Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia (CAP-Marker)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01018199|
Recruitment Status : Withdrawn (Changes in the profile of patients assisted by the hospital)
First Posted : November 23, 2009
Last Update Posted : February 3, 2016
|Condition or disease||Intervention/treatment||Phase|
|Community-acquired Pneumonia||Other: CRP Other: PCT||Not Applicable|
• Patients and settings:
All adult (> 18 years old) patients with diagnosis community-acquired pneumonia will receive initial antibiotic therapy based on local guidelines and susceptibility patterns, according to the decision of the treating physician.Patients will be randomly assigned to one of two groups, which respectively include PCR and PCT clinical procedure protocol. Randomization will be done using a table of random numbers generated by computer. For practical reasons the doctors treating the patients in question have science group in which the patient was included.
Patients included in the two groups will have baseline assessment during the first day of study:
- Clinical evaluation of basic
- Start of antibiotic therapy
- Inclusion in the study
- Randomization (after signing the Informed Consent)
They will have circulating PCT and CRP levels measured at baseline and days 1,2,3 e 5 in both groups.
Group 1 - CRP group: the duration of antibiotic therapy will be based on circulating CRP levels.
Group 2 - PCT group: the duration of antibiotic therapy will be based on circulating PCT levels.
Patients enrolled in the study will undergo daily measurements of plasma CRP (Dry Chemistry - Johnsons & Johnsons) and PCT (BRAHMS PCT VIDAS) levels up to day 5, and then, every 48hr in patients remaining in the ICU, and every 5 days in those transferred to the ward. Patients will be followed up 28 days, or until death or hospital transference, which comes first. PCT and CRP results will be released in sealed envelopes. During the study period, only the results corresponding to the patient randomization group will be open; i.e., CRP for CRP group patients and PCT for PCT group patients.
Criteria for antibiotic interruption:
The investigators will propose the interruption of antibiotics if:
- The patients is clinically stable, without signs of active infection
- CRP group: a relative reduction of 50% in baseline CRP levels, or a value lower than 25mg/dl is reached.
- PCT group: a relative reduction of 90% in baseline PCT levels, or if a absolute value lower than 0.1 ng/ml is reached.
The final decision regarding antibiotic therapy will be always let to the discretion of the treating physician.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Use of Procalcitonin (PCT) and C-reactive Protein (CRP) to Guide Antibiotic Therapy in Community Acquired Pneumonia: a Randomized Controlled Trial|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||August 2018|
Experimental: Group 1- C-reactive protein (CRP) guided antibiotic therapy
Intervention on antibiotic therapy will be based on circulating RCP levels
C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
Active Comparator: Group 2 - procalcitonin (PCT) guided antibiotic therapy
Intervention on antibiotic therapy will be based on circulating PCT levels
Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
- Duration of antibiotic therapy for the first episode of infection [ Time Frame: 28 days ]
- Total antibiotic exposure days per 1,000 days [ Time Frame: 28 days ]
- Days alive without antibiotics [ Time Frame: 28 days ]
- All cause 28-day mortality [ Time Frame: 28 days ]
- clinical cure rate [ Time Frame: 28 days ]
- Infection relapse (diagnosed less than 48h after antibiotic discontinuation) [ Time Frame: 28 days ]
- Length of hospitalization stay [ Time Frame: Whole hospitalization ]
- In-hospital mortality [ Time Frame: 28 days ]
- Nosocomial infection rate [ Time Frame: 28 days ]
- Nosocomial superinfection (diagnosed more than 48hous after discontinuation of the antibiotic therapy given to the first episode of infection) [ Time Frame: 28 days ]
- Isolation of resistant bacteria [ Time Frame: 28 days ]
- All cause 90-day mortality [ Time Frame: 90 days ]
- costs of hospitalization [ Time Frame: Whole hospitalization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01018199
|Hospital das Clínicas - Universidade Federal de Minas Gerais|
|Belo Horizonte, Minas Gerais, Brazil|
|Principal Investigator:||Vandack A Nobre, PhD||Medical School of the Federal University of Minas Gerais|
|Study Chair:||Karla F Finotti, MD||Medical School of the Federal University of Minas Gerais|